109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
细胞外囊泡载药递送系统在癌症治疗中的研究进展
Authors Huang Z, Cheng J, Deng Z, Liu C, Huang T, Lin W
Received 25 June 2025
Accepted for publication 15 October 2025
Published 27 October 2025 Volume 2025:20 Pages 13007—13037
DOI https://doi.org/10.2147/IJN.S548006
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Dr Yan Shen
Zhiben Huang,1,* Jiaqing Cheng,2,* Zhimin Deng,1 Chunjiang Liu,1 Tianying Huang,2 Wansong Lin3,4
1College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350108, People’s Republic of China; 2The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, 350122, People’s Republic of China; 3Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, People’s Republic of China; 4Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, 350014, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wansong Lin, Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, People’s Republic of China, Email linwansong@fjzlhospital.com
摘要：细胞外囊泡（EVs）凭借其独特的生物学优势与理化性质，已成为肿瘤治疗领域备受关注的纳米级药物递送系统。这类源于细胞的纳米颗粒不仅免疫原性低、具备天然靶向能力，还能在细胞间精准传递蛋白质、核酸等生物活性分子。近年来，随着工程化EVs研究取得显著进展，以EVs为载体的药物递送系统在肿瘤部位的递送效率与精准性得到进一步提升。本文概述了EVs的生物发生机制、组成结构，及其相较于传统纳米载体的独特优势，重点探讨了其在癌症治疗中的应用潜力。同时，详细介绍了EVs载药方法及提升肿瘤靶向性的前沿工程策略，并系统梳理了其在化疗药物递送、核酸类药物治疗、肿瘤疫苗及多功能诊疗一体化等方向的应用。此外，本文还总结了相关临床试验，指出当前临床转化面临的关键挑战，包括规模化生产瓶颈和监管路径不明确等问题。突破这些难题将推动EVs发展成为精准化、个性化癌症治疗的重要工具。本综述为EVs介导的治疗策略在肿瘤治疗领域的研究现状与未来前景提供了深入见解。
1College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350108, People’s Republic of China; 2The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, 350122, People’s Republic of China; 3Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, People’s Republic of China; 4Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, 350014, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wansong Lin, Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, People’s Republic of China, Email linwansong@fjzlhospital.com
摘要：细胞外囊泡（EVs）凭借其独特的生物学优势与理化性质，已成为肿瘤治疗领域备受关注的纳米级药物递送系统。这类源于细胞的纳米颗粒不仅免疫原性低、具备天然靶向能力，还能在细胞间精准传递蛋白质、核酸等生物活性分子。近年来，随着工程化EVs研究取得显著进展，以EVs为载体的药物递送系统在肿瘤部位的递送效率与精准性得到进一步提升。本文概述了EVs的生物发生机制、组成结构，及其相较于传统纳米载体的独特优势，重点探讨了其在癌症治疗中的应用潜力。同时，详细介绍了EVs载药方法及提升肿瘤靶向性的前沿工程策略，并系统梳理了其在化疗药物递送、核酸类药物治疗、肿瘤疫苗及多功能诊疗一体化等方向的应用。此外，本文还总结了相关临床试验，指出当前临床转化面临的关键挑战，包括规模化生产瓶颈和监管路径不明确等问题。突破这些难题将推动EVs发展成为精准化、个性化癌症治疗的重要工具。本综述为EVs介导的治疗策略在肿瘤治疗领域的研究现状与未来前景提供了深入见解。